Trial
NCT00580073
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Sanofi; Bristol-Myers Squibb; Eli Lilly and Company
Condition
Rectal Cancer
Intervention
FOLFOX4
Why stopped
Loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-13